AKT1 and breast cancer: Indeed, emerging evidence has shown that VPS34 can modulate the basal activity of mTOR complex 1 (mTORC1) in animal models and the glycogen synthetase kinase 3 (GSK3) pathway in breast cancer patients treated with AKT inhibitors [33].